CD274 and non-small cell lung carcinoma: In the present study, we thus aimed to investigate the clinical utility of this metabolic score on the prognostication of clinical outcomes, in a multicenter cohort of untreated patients with advanced NSCLC with PD-L1 TPS of at least 50%, undergoing first-line pembrolizumab.